Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “immunotherapy”

175 pharma patents match "immunotherapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 175
Index total 30,257
Page 6 / 8

Quick answer

This filtered view shows 175 pharmaceutical patents matching "immunotherapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

175 results for “immunotherapy” · 30,257 patents in full index Clear search

  1. US 10537595

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted

  2. US 10463697

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted

  3. US 10441645

    MSLN targeting DNA vaccine for cancer immunotherapy

    Vaximm AG · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted

  4. US 10426797

    Compositions and methods for treating cancer with anti-CD33 immunotherapy

    United State of America, As Represented by the Secretary, Dept. of Health and Human Services · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted

  5. US 10420799

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted

  6. US 10398734

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Sep 3, 2019 · Expires Aug 29, 2039

    granted

  7. US 10392439

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted

  8. US 10363273

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  9. US 10301365

    Met e 1 tropomyosin variants for use in allergen-specific immunotherapy

    The Regents of the University of California · Granted May 28, 2019 · Expires May 23, 2039

    granted

  10. US 10272113

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  11. US 10258678

    Indoleamine 2,3-dioxygenase based immunotherapy

    IO Biotech ApS · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted

  12. US 10167337

    Combination immunotherapy for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Jan 1, 2019 · Expires Dec 27, 2038

    granted

  13. US 10166257

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 1, 2019 · Expires Dec 27, 2038

    granted

  14. US 10166277

    Vault immunotherapy

    THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Jan 1, 2019 · Expires Dec 27, 2038

    granted

  15. US 10130658

    Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

    Provectus Pharmatech, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted

  16. US 10130659

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted

  17. US 10117915

    Modulation of yeast-based immunotherapy products and responses

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted

  18. US 10036751

    Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines and method of prognosticating survival rate in glioblastoma mulztiforme patient after treatment

    China Medical University Hospital · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted

  19. US 10023637

    Combination immunotherapy for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  20. US 9920100

    Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy

    The Regents of the University of California · Granted Mar 20, 2018 · Expires Mar 15, 2038

    granted

  21. US 9920297

    Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene WT1

    Vaximm AG · Granted Mar 20, 2018 · Expires Mar 15, 2038

    granted

  22. US 9907820

    Polyclonal gamma delta T cells for immunotherapy

    The Board of Regents of the University of Texas System · Granted Mar 6, 2018 · Expires Mar 1, 2038

    granted

  23. US 9855330

    Granulysin in immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 2, 2018 · Expires Dec 28, 2037

    granted

  24. US 9433666

    Indoleamine 2,3-dioxygenase based immunotherapy

    IO Biotech ApS · Granted Sep 6, 2016 · Expires Sep 1, 2036

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.